News Release

Journal Article Highlights AlbuVoid™ in Rheumatoid Arthritis Biomarker Study

MONMOUTH JUNCTION, NJ, January 24, 2018 -- Biotech Support Group reports on a new research report which highlights the simplicity and efficiency of their proteomic sample preparation technology as an initial enrichment step for synovial fluid and serum analysis.

The citation is:

Mihara, Keisuke, et al. "Identification of Specific Protein Markers of Rheumatoid Arthritis in Synovial Fluid and Serum." Journal of Hard Tissue Biology 27.1 (2018): 55-58.

Rheumatoid arthritis (RA) is characterized by chronic inflammation, hyperproliferation of synovial cells, and bone destruction. In this study, AlbuVoid™ was used to remove Albumin and enrich the low abundance proteomes from serum and synovial fluid. The article states “…albumin and globulin were eliminated by using an AlbuVoid Albumin Depletion Kit (Biotech Support, Monmouth Junction, NJ).” The investigation searched for RA-specific protein/peptide markers to facilitate early and sensitive diagnosis of RA using three different methods: a protein chip, 2D-gel, and western blotting. The study identified several RA-specific protein and peptide marker candidates. 

“We are very pleased to see that AlbuVoid™ provided the enrichment necessary to uncover biomarker candidates for Rheumatoid Arthritis. Using three different analytical reporting methods, the versatility of AlbuVoid™ enrichment from both synovial fluid and serum is demonstrated” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact: Matthew Kuruc 732-274-2866 mkuruc@biotechsupportgroup.com